- The report contains detailed information about Vernalis plc that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Vernalis plc. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The Vernalis plc financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes Vernalis plc competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Vernalis plc business.
About Vernalis plc
Vernalis plc, a development stage pharmaceutical company, engages in de novo structure and fragment-based drug discovery, and pre-clinical and clinical development primarily in Europe and North America.
The company has seven product candidates in clinical development (two of which are partnered), two programmes in pre-clinical (one with a partner) and other research programmes.
The companys marketed products include Frovatriptan, a 5-HT1B/1D receptor agonist, which is approved as an acute oral treatment for migraine headache and its associated symptoms; and Apokyn, an acute intermittent therapy for the treatment of re-emergence of Parkinsons disease symptoms associated with advanced Parkinsons disease.
V3381/Indantadol: It is a Phase IIb study small molecule with a dual mechanism for the treatment of neuropathic pain.
V1512/Levodopa methyl ester/carbidopa: It is a Phase II trial product for Parkinsons disease treatment ((moderate/advanced).
V10153: It is a Phase IIa recombinant human thrombolytic protein for the treatment of acute ischemic stroke.
V2006 (BIIB014): It is an adenosine A2A receptor antagonist in Phase IIa study for the treatment of Parkinsons disease. Biogen Idec has marketing rights for this product.
V85546: It is a Phase I study selective MMP 12 inhibitor for inflammation.
V24343: It is a Phase I study cannabinoid type 1 receptor antagonist for the treatment of obesity, diabetes, and related disorders.
NVP-AUY922: It is an Hsp90 inhibitor, which is in Phase I program for the treatment of a range of cancers, including solid tumors and hematological cancers. Novartis has marketing rights for this product.
Hsp90 inhib. (Oral): This product is in Phase I clinical stage and is used for the treatment of Cancer. Novartis has marketing rights for this product.
V158866 Fatty Acid Amide Hydrolase: It is a pre-clinical stage product for pain management.
The company also develops programs that inhibit Checkpoint Kinase 1 inhibitors to identify product candidates that enhance the anti-tumor efficacy of current cytotoxic agents without increasing their toxicity to non-cancerous tissues.
The company has an ongoing multi-target collaboration with Servier in oncology for protein-protein interactions.
In July 2008, the company sold Apokyn and Vernalis Pharmaceuticals Inc, its U.S. Commercial Operations, to Ipsen SA.
Vernalis plc was founded in 1986.
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
1. VERNALIS PLC COMPANY PROFILE
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. VERNALIS PLC BUSINESS OVERVIEW
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. VERNALIS PLC SWOT ANALYSIS
4. VERNALIS PLC FINANCIAL ANALYSIS
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. VERNALIS PLC COMPETITORS AND INDUSTRY ANALYSIS
5.1. Vernalis plc Direct Competitors
5.2. Comparison of Vernalis plc and Direct Competitors Financial Ratios
5.3. Comparison of Vernalis plc and Direct Competitors Stock Charts
5.4. Vernalis plc Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
5.4.2. Vernalis plc Industry Position Analysis
6. VERNALIS PLC NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. VERNALIS PLC EXPERTS REVIEW1
7.1. Experts Opinion
7.2. Experts Estimates
8. VERNALIS PLC ENHANCED SWOT ANALYSIS2
9. UK PESTEL ANALYSIS2
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. VERNALIS PLC IFE, EFE, IE MATRICES2
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. VERNALIS PLC PORTER FIVE FORCES ANALYSIS2
12. VERNALIS PLC VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF TABLES
Vernalis plc Key Facts
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Vernalis plc Key Executives
Key Executives Biographies1
Key Executives Compensations1
Vernalis plc Major Shareholders
Vernalis plc History
Vernalis plc Products
Revenues by Segment
Revenues by Region
Vernalis plc Offices and Representations
Vernalis plc SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Vernalis plc Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Vernalis plc Capital Market Snapshot
Vernalis plc Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Vernalis plc Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Vernalis plc Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Revenue Estimates Trend1
Earnings Estimates Trend1
LIST OF FIGURES
Vernalis plc Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Vernalis plc 1-year Stock Charts
Vernalis plc 5-year Stock Charts
Vernalis plc vs. Main Indexes 1-year Stock Chart
Vernalis plc vs. Direct Competitors 1-year Stock Charts
Vernalis plc Article Density Chart
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
Enhanced SWOT Analysis
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Key Factors Examined by PESTEL Analysis:
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
Porter Five Forces Analysis
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
- Tangible resources
- Intangible resources
- Innovation and Creativity
- Organizational capabilities
- Costly to imitate?
- Organized properly?